公开(公告)号：US10329567B2

公开(公告)日：2019-06-25

申请号：US16021165

申请日：2018-06-28

Applicant: National University Corporation Tokyo Medical and Dental University ,  Osaka University

Inventor： Takanori Yokota ,  Kazutaka Nishina ,  Satoshi Obika ,  Hidehiro Mizusawa

IPC: C12N15/09 ,  C12N15/113 ,  C12N15/11

Abstract: A method of reducing the level of a transcription product in a cell comprising contacting with the cell a composition comprising a double-stranded nucleic acid complex comprising a first nucleic acid strand annealed to a second nucleic acid strand, wherein: (i) the first nucleic acid strand hybridizes to the transcription product and comprises (a) a region consisting of at least 4 consecutive nucleotides that are recognized by RNase H when the strand is hybridized to the transcription product, (b) one or more nucleotide analogs located on 5′ terminal side of the region, (c) one or more nucleotide analogs located on 3′ terminal side of the region and (d) a total number of nucleotides and nucleotide analogs ranging from 8 to 35 nucleotides and (ii) the second nucleic acid strand comprises (a) nucleotides and optionally nucleotide analogs and (b) at least 4 consecutive RNA nucleotides.

公开(公告)号：US20190177455A1

公开(公告)日：2019-06-13

申请号：US16326957

申请日：2017-08-23

Applicant: DAIKIN INDUSTRIES, LTD. ,  OSAKA UNIVERSITY

Inventor： Akira HARADA ,  Hiroyasu YAMAGUCHI ,  Yoshinori TAKASHIMA ,  Suguru NOMIMURA ,  Hikaru ARAMOTO ,  Ryohei IKURA ,  Masaki NAKAHATA ,  Kazuhisa IWASO ,  Kentarou HIRAGA ,  Akinari SUGIYAMA ,  Fumihiko YAMAGUCHI ,  Takashi NOMURA

IPC: C08F220/56 ,  C08F220/18 ,  C08J3/11 ,  C09D133/26 ,  C09D133/06 ,  C09K3/10

Abstract: An object of the present invention is to provide a macromolecular material that exhibits excellent elongation. The first macromolecular material of the present invention contains the first polymer containing the first structural unit and the second polymer containing the second structural unit. The first structural unit has a guest group in its side chain, and the second structural unit has a host group in its side chain. At least one of the first and the second polymers contains at least one fluorine group. The second macromolecular material of the present invention contains the first structural unit having a guest group in its side chain, the second structural unit having a host group in its side chain, and the third structural unit other than the first and second structural units. At least one of the first, the second, and the third structural units contains at least one fluorine group.

公开(公告)号：US10293026B2

公开(公告)日：2019-05-21

申请号：US15509777

申请日：2015-09-08

Applicant: Osaka University

Inventor： Rieko Ikeda ,  Mariko Kuroda ,  Toshihide Yamashita

IPC: A61K38/18 ,  C07K14/50 ,  C12N15/00 ,  A61K31/713

Abstract: An object of the present invention is to provide a pharmaceutical preparation that can promote the proliferation of oligodendrocyte precursor cells to effectively prevent or treat a demyelinating disease. FGF21 acts to promote the proliferation of oligodendrocyte precursor cells, and thus, the administration of FGF21, DNA encoding FGF21, an FGF21 production-promoting substance, and/or FGF21-producing cells is effective for preventing or treating a demyelinating disease.

公开(公告)号：US10286222B2

公开(公告)日：2019-05-14

申请号：US13378333

申请日：2010-06-11

Applicant: Atsushi Nishikawa ,  Youichi Saitoh ,  Taishi Fukushima ,  Masaki Sekino ,  Kuniyoshi Uchida

Inventor： Atsushi Nishikawa ,  Youichi Saitoh ,  Taishi Fukushima ,  Masaki Sekino ,  Kuniyoshi Uchida

IPC: A61N2/00 ,  A61N2/02 ,  A61B5/05 ,  A61B5/00 ,  A61B90/14

Abstract: Provided is a magnetic stimulator for applying magnetic stimulation to a particular portion of a subject. This magnetic stimulator includes: a magnetic field generating means including at least a stimulation coil configured to generate a dynamic magnetic field so as to apply the magnetic stimulation; a coil holder operated to displace a relative position of the magnetic field generating means with respect to the particular portion of the subject; a plurality of magnetic field sensors each configured to detect the magnetic field generated by the magnetic field generating means; and a user interface section configured to provide instruction information based on a result of the detection of the magnetic field generated by the magnetic field generating means, the instruction information indicating an operation of displacement to be performed using the coil holder, the detection being made by the magnetic field sensors either before or during the magnetic stimulation.

公开(公告)号：US20190083415A1

公开(公告)日：2019-03-21

申请号：US16082594

申请日：2017-03-06

Applicant: OSAKA UNIVERSITY ,  NATIONAL INSTITUTE FOR MATERIALS SCIENCE ,  NIPPON ZOKI PHARMACEUTICAL CO., LTD.

Inventor： Hiroyuki TANAKA ,  Kiyoshi OKADA ,  Hideki YOSHIKAWA ,  Koji SUZUKI ,  Mitsuhiro EBARA

IPC: A61K9/70 ,  A61K31/714 ,  A61K35/36 ,  A61K38/18 ,  A61K47/34 ,  A61K47/32 ,  A61K47/36 ,  A61P25/02

Abstract: Provided is a sustained release sheet that includes a drug for treating nerve injury, wherein the sheet is applied to a nerve injury site, can maintain a high concentration of the drug over a long period, and promotes nerve regeneration without stimulating the nerves, even when the sheet is implanted in the periphery of the nerve injury site. Also provided is a production method for the sheet. This sustained drug release sheet for treating nerve injury is a sheet comprising a non-woven fabric that is formed from nanofibers each containing a drug such as vitamin B12 and a biocompatible polymer such as a biodegradable aliphatic polyester, and is implanted in the periphery of the nerve injury site to promote nerve regeneration.

公开(公告)号：US10232153B2

公开(公告)日：2019-03-19

申请号：US15126553

申请日：2015-02-26

Applicant: OSAKA UNIVERSITY ,  HOYA CORPORATION

Inventor： Kohji Nishida ,  Takeshi Soma ,  Yusuke Goto ,  Kikuo Mitomo

IPC: A61M31/00 ,  A61F2/00 ,  A61F2/14 ,  A61F9/007 ,  A61F9/00

Abstract: A therapeutic instrument (20), includes: a support member (25) having a tongue-shaped supporting portion (50) for supporting a sheet-like therapeutic agent; a nozzle member (23) having a cylindrical portion (30) in which the supporting portion (50) supporting the therapeutic agent can be housed, and having an opening (34) through which the supporting portion (50) can be loaded and unloaded in/from a tip of the cylindrical portion (30); a syringe unit (22) that acts a positive pressure in the cylindrical portion (30) for pushing-out the therapeutic agent housed in the cylindrical portion (30) together with the supporting portion (50) to outside the cylindrical portion (30) through the opening (34); and a water flow forming part including a plurality of protrusions (53) formed on a surface of the supporting portion (50) so as to form a water flow at a place where the supporting portion (50) and the therapeutic agent are facing each other, when a medical water is fed into the cylindrical portion (30) in a state in which the therapeutic agent is housed in the cylindrical portion (30) together with the supporting portion (50).

公开(公告)号：US20190056336A1

公开(公告)日：2019-02-21

申请号：US16081249

申请日：2017-02-22

Applicant: SHIMADZU CORPORATION ,  OSAKA UNIVERSITY

Inventor： Takahiro DOKI ,  Koichi TANABE ,  Toshinori YOSHIMUTA ,  Kenji KIMURA ,  Akihiro NISHIMURA ,  Taro SHIRAI ,  Satoshi SANO ,  Akira HORIBA ,  Takayoshi SHIMURA ,  Heiji WATANABE ,  Takuji HOSOI

IPC: G01N23/041 ,  G01N23/20 ,  A61B6/00

Abstract: [PROBLEM TO BE SOLVED] To provide a radiation phase contrast imaging device having a small device configuration[SOLVING MEANS] The present invention focused on the findings that the distance between the phase grating 5 and the FPD 4 does not need to be the Talbot distance. The distance between the phase grating 5 and the FPD 4 can be more freely set. However, a self-image cannot be detected unless the self-image is sufficiently magnified with respect to the phase grating 5. The degree on how much the self-image is magnified on the FPD 4 with respect to the original phase grating 5 is determined by a magnification ratio X2/X1. Therefore, in the present invention, the magnification ratio is set to be the same as the magnification ratio in a conventional configuration. With this, even if the distance X2 between the radiation source 3 and the FPD 4 is reduced, a situation in which the self-image cannot be detected by the FPD 4 due to the excessively small size thereof does not occur.

公开(公告)号：US10209504B2

公开(公告)日：2019-02-19

申请号：US15937684

申请日：2018-03-27

Applicant: OLYMPUS CORPORATION ,  NATIONAL INSTITUTE OF INFORMATION AND COMMUNICATIONS TECHNOLOGY ,  OSAKA UNIVERSITY ,  NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY

Inventor： Hirokazu Kubo ,  Shigehito Miki ,  Hirotaka Terai ,  Taro Yamashita ,  Tokuko Haraguchi ,  Yasushi Hiraoka ,  Masataka Kinjo

IPC: G02B21/18 ,  G02B21/00 ,  G01N21/64 ,  G02B21/28

Abstract: Provided is a light detecting device including: a light path branching unit that branches a single detection light path of fluorescence from a specimen, into a plurality of branched light paths; a plurality of light detectors that are provided to the respective branched light paths branched by the light path branching unit and that include an SSPD or Geiger mode APD to detect the fluorescence; and a signal adder that generates a single image signal in accordance with the detection signals outputted from the plurality of light detectors.

公开(公告)号：US20190008886A1

公开(公告)日：2019-01-10

申请号：US16068163

申请日：2017-01-05

Applicant: OSAKA UNIVERSITY ,  NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY ,  NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITION

Inventor： Masayuki NAKAMORI ,  Hideki MOCHIZUKI ,  Satoshi OBIKA ,  Takanori YOKOTA ,  Tetuya NAGATA ,  Yuya KASAHARA

IPC: A61K31/712 ,  C12N15/113 ,  C07K14/47 ,  A61P25/28 ,  A61P25/16

Abstract: The present invention can provide a nucleic acid medicine which has a higher effect and a more prolonged effect of inhibiting the expression of α-synudein can be provided. Disclosed is the oligonucleotide or a pharmacologically acceptable salt thereof, the oligonucleotide containing at least one nucleoside structure represented by Formula (I): (where each of Base and A are defined substituent or structure), can bind to an α-synudein gene, has activity for inhibiting expression of the α-synudein gene, and is complementary to the α-synudein gene, and the oligonucleotide has a length of twelve to twenty bases.

公开(公告)号：US10166086B2

公开(公告)日：2019-01-01

申请号：US14110837

申请日：2012-05-17

Applicant: Kunio Awazu ,  Katsunori Ishii ,  Naota Akikusa ,  Tadataka Edamura ,  Hirofumi Kan

Inventor： Kunio Awazu ,  Katsunori Ishii ,  Naota Akikusa ,  Tadataka Edamura ,  Hirofumi Kan

IPC: A61C1/00 ,  A61C3/02

Abstract: A dental therapy apparatus which enables a dental therapy more surely and less invasively is provided. A dental therapy apparatus (10A) comprises a laser light source (11) emitting laser light (L) having a wavelength within a wavelength region of 5.7 to 6.6 μm; a controller (12) pulse-driving the laser light source and controlling at least one of pulse width and repetition frequency of pulsed laser light emitted from the laser light source; and an irradiation optical system for irradiating a tooth (20) including a carious part (21) with the light emitted from the laser light source. In this dental therapy apparatus, the controller controls at least one of the pulse width and repetition frequency of the pulsed light, so as to selectively cut the carious part (21).